Benzinga · Mar 5, 2026
WL
NYSE · WLY
John Wiley & Sons, Inc.
Communication Services · Publishing
$49.33
Down-$0.49 (-0.99%)
Updated Sep 16, 2026, 3:42 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.69B
- P/E ratio
- 16.57
- Dividend yield
- 2.87%
- 52-week range
- $35.66 – $57.45
- Volume
- 634.33K
- Avg. volume
- 459.27K
Price performance
WLY price history
1M range · 20 trading sessions · Daily adjusted prices
WLY closed at $49.33 after 20 trading sessions, down 3.48% for the selected period.
- Last close
- $49.33
- Period change
- -3.48%
- Period low
- $47.03
- Period high
- $54.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $46.82 | $49.51 | $46.82 | $49.33 | 634.33K |
| Sep 14, 2026 | $47.75 | $48.68 | $47.435 | $48.43 | 487.97K |
| Sep 11, 2026 | $47.40 | $47.52 | $46.80 | $47.03 | 509.14K |
| Sep 10, 2026 | $47.98 | $48.6708 | $47.0834 | $47.24 | 593.54K |
| Sep 9, 2026 | $48.36 | $48.53 | $47.1301 | $47.99 | 610.73K |
| Sep 8, 2026 | $48.24 | $48.955 | $47.01 | $48.68 | 691.03K |
| Sep 4, 2026 | $49.50 | $51.15 | $46.51 | $48.19 | 1.05M |
| Sep 3, 2026 | $48.84 | $54.80 | $48.84 | $50.66 | 1.14M |
| Sep 2, 2026 | $53.07 | $54.81 | $50.89 | $51.05 | 1.23M |
| Sep 1, 2026 | $52.24 | $53.33 | $52.18 | $52.39 | 531.51K |
| Aug 31, 2026 | $53.54 | $54.00 | $51.79 | $52.39 | 686.34K |
| Aug 28, 2026 | $54.16 | $54.80 | $53.245 | $53.71 | 380.78K |
| Aug 27, 2026 | $53.23 | $54.21 | $52.69 | $54.04 | 247.17K |
| Aug 26, 2026 | $53.65 | $53.98 | $52.85 | $53.11 | 319.44K |
| Aug 25, 2026 | $53.35 | $54.16 | $52.68 | $53.89 | 360.09K |
| Aug 24, 2026 | $51.91 | $53.24 | $51.91 | $53.20 | 251.58K |
| Aug 21, 2026 | $51.75 | $52.285 | $51.42 | $51.58 | 381.5K |
| Aug 20, 2026 | $51.46 | $52.82 | $51.46 | $52.08 | 324.75K |
| Aug 19, 2026 | $51.26 | $52.05 | $50.43 | $51.97 | 426.87K |
| Aug 18, 2026 | $51.37 | $52.39 | $50.94 | $51.11 | 439.1K |
Latest WLY news
The latest Smart Investors Daily articles mentioning WLY.
Stock researchCompany · Overview
WLY research
Overview
Company profile and research snapshot.
Company profile
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2022 | CJS Securities | Market Outperform | — |
| Aug 29, 2022 | CJS Securities | Market Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Mar 4, 2026
Earnings To Watch: Wiley (WLY) Reports Q4 Results Tomorrow
Academic publishing company John Wiley & Sons (NYSE:WLY) will be announcing earnings results this Thursday morning. Here’s what to expect.
Yahoo · Mar 3, 2026
Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care
HOBOKEN, N.J., March 03, 2026--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians using OpenEvidence at the point of care can rely on content from hundreds of Wiley
Benzinga · Mar 3, 2026
John Wiley & Sons Announces Strategic Partnership With OpenEvidence To Integrate AI Tools Into Medical Journal Research
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
